Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST EBITDA Margin
EBITDA as a percentage of revenue.
Aquestive Therapeutics, Inc.NASDAQ: AQST
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -27.7%
EBITDA Margin was -27.7% in Q1 FY2026, up 184.6 pp from a year earlier. On a trailing-twelve-month basis it was -102.7%, down 35.0 pp year over year. Over 3 fiscal years it narrowed by 65.4 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -88.9% for the fiscal year ending Dec 2026, up from -148.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -27.7%+183.3 pp QoQ
- Last fiscal yearDec 2025
- -148.4%-102.2 pp YoY
- LTMMar 2026
- -102.7%-35.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -148.4%
- Year-over-year change
- -102.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -148.4% | -102.2pp |
| FY2024 | 2024-12-31 | -46.2% | -48.6pp |
| FY2023 | 2023-12-31 | 2.3% | +85.3pp |
| FY2022 | 2022-12-31 | -83.0% | +5.7pp |
| FY2021 | 2021-12-31 | -88.8% | — |
EBITDA Margin vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 EBITDA Margin of -102.7% is the lowest of the 10 companies compared; the peer median is 10.2%.
- Its year-over-year change of -35.0 pp is the 9th highest of 10, against a peer median of -9.0 pp.
- Over three fiscal years its change of -65.4 pp compares with a peer median of +14.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 114.9% | +263.4 pp | +343.9 pp | |
| LTM Mar 2026 | 76.6% | +26.5 pp | +14.0 pp | |
| LTM Mar 2026 | 26.6% | -9.0 pp | +0.2 pp | |
| LTM Mar 2026 | 14.7% | +16.6 pp | +67.2 pp | |
| LTM Sep 2026 | 10.2% | -18.5 pp | +17.0 pp | |
| LTM Jun 2026 | -1.9% | -26.9 pp | -17.1 pp | |
| LTM Mar 2026 | -2.2% | +0.3 pp | +26.1 pp | |
| LTM Mar 2026 | -4.3% | -12.3 pp | +5.9 pp | |
| LTM Mar 2026 | -62.6% | -41.0 pp | -64.2 pp | |
| LTM Mar 2026 | -102.7% | -35.0 pp | -65.4 pp | |
| Peer median (excluding AQST) | 10.2% | -9.0 pp | +14.0 pp | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | 14.99M | 19.39M | 20.83M | 17.87M | 17.15M |
| Gross Profit | 35.84M | 28.29M | 29.75M | 39.69M | 27.39M |
| Gross Margin | 70.5% | 59.3% | 58.8% | 69.0% | 61.5% |
| Research & Development | 17.05M | 17.48M | 13.1M | 20.28M | 17.19M |
| Selling, General & Admin | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| Operating Expenses | 70.52M | 70.36M | 44.85M | 70.46M | 97.04M |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 559K |
| EBITDA | (45.11M) | (39.58M) | 1.18M | (26.62M) | (66.13M) |
| EBITDA Margin | -88.8% | -83.0% | 2.3% | -46.2% | -148.4% |
| Operating Income | (34.68M) | (42.07M) | (15.1M) | (30.77M) | (69.65M) |
| Operating Margin | -68.2% | -88.2% | -29.9% | -53.5% | -156.4% |
| Interest Income | 423K | 99K | 16.32M | 3.44M | 0 |
| Interest Expense | 22.46M | 12.44M | 7.46M | 16.82M | 17.1M |
| Other Income / Expenses | (35.86M) | (12.34M) | 7.48M | (13.38M) | (14.13M) |
| Income Before Tax | (70.54M) | (54.41M) | (7.63M) | (44.15M) | (83.78M) |
| Pre-Tax Margin | -138.8% | -114.1% | -15.1% | -76.7% | -188.1% |
| Income Tax Expense | 0 | 0 | 245K | (14K) | 0 |
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Net Margin | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
| EPS (Basic) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| EPS (Diluted) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| Weighted Avg Shares | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Weighted Avg Shares (Diluted) | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.